Abstract
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerReferences
- DNA-repair defects and olaparib in metastatic prostate cancer.N Engl J Med. 2015; 373: 1697-1708
- Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer.Eur Urol. 2016; 69: 992-995
- Inherited DNA-repair gene mutations in men with metastatic prostate cancer.N Engl J Med. 2016; 375: 443-453
- Baseline prostate-specific antigen testing at a young age.Eur Urol. 2012; 61: 1-7
- Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death.Eur Urol. 2017; 71: 740-747
- Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer.Eur Urol. 2017; 72: 34-42
- Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study.J Natl Cancer Inst. 2016; 108
- Concordance of survival in family members with prostate cancer.J Clin Oncol. 2008; 26: 1705-1709
- Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.J Urol. 2010; 183: 946-950
- Familial risk and heritability of cancer among twins in Nordic countries.JAMA. 2016; 315: 68-76
- Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.BMJ. 2013; 346: f2023
- The genetic epidemiology of prostate cancer and its clinical implications.Nat Rev Urol. 2014; 11: 18-31
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.Genet Med. 2015; 17: 405-424
- Cancer incidence in BRCA1 mutation carriers.J Natl Cancer Inst. 2002; 94: 1358-1365
- Germline BRCA1 mutations increase prostate cancer risk.Br J Cancer. 2012; 106: 1697-1701
- Cancer risks in BRCA2 mutation carriers.J Natl Cancer Inst. 1999; 91: 1310-1316
- BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.Br J Cancer. 2011; 105: 1230-1234
- Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer.Eur Urol. 2015; 68: 186-193
- Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.J Clin Oncol. 2013; 31: 1748-1757
- Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.Clin Cancer Res. 2010; 16: 2115-2121
- Early detection of prostate cancer: AUA Guideline.J Urol. 2013; 190: 419-426
- NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.J Natl Compr Canc Netw. 2016; 14: 509-519
- Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening.CA Cancer J Clin. 2016; 66: 96-114
US Preventive Services Task Force (USPSTF), Screening for Prostate Cancer, Available at: http://www.screeningforprostatecancer.org, Accessed July 6, 2017.
- Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.Eur Urol. 2014; 66: 489-499
- Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.JAMA. 1993; 270: 860-864
- Prostate Cancer Awareness Week: September 22 to 28, 1997.CA Cancer J Clin. 1997; 47: 288-296
- Age-specific reference ranges for serum prostate-specific antigen in black men.N Engl J Med. 1996; 335: 304-310
- Ethnic differences in distribution of serum prostate-specific antigen: a study in a healthy Chinese male population.Urology. 2004; 63: 722-726
- Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.Urology. 2005; 66: 547-551
- Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.N Engl J Med. 2004; 350: 2239-2246
- Screening men at increased risk for prostate cancer diagnosis: model estimates of benefits and harms.Cancer Epidemiol Biomarkers Prev. 2017; 26: 222-227
National Comprehensive Cancer Network, Genetic/Familial High-Risk Assessment: Breast and Ovarian (Version 2.2017), Available at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf, Accessed July 6, 2017.
- Comparative effectiveness of alternative prostate-specific antigen–based prostate cancer screening strategies: model estimates of potential benefits and harms.Ann Intern Med. 2013; 158: 145-153
- Projecting benefits and harms of novel cancer screening biomarkers: a study of PCA3 and prostate cancer.Cancer Epidemiol Biomarkers Prev. 2015; 24: 677-682
- Online tool to guide decisions for BRCA1/2 mutation carriers.J Clin Oncol. 2012; 30: 497-506